Hoth Therapeutics Secures U.S. Patent for HT-KIT, Strengthening Oncology IP

What happened

Hoth Therapeutics received a U.S. Notice of Allowance for its HT-KIT antisense oncology platform, covering composition-of-matter and methods targeting MS4A6A pre-mRNA splicing. This patent adds to the company's IP portfolio, which already includes granted patents in Japan and China, bolstering its position in KIT-driven cancers. However, the company remains a pre-revenue microcap with a thin cash runway of under a year at current burn rates, having burned $9.78M in the first nine months of 2025. The only mid-stage asset, HT-001, is still in Phase 2 with qualitative data, and the share count has increased ~88% in 2025 due to equity issuance. While the patent is a positive step, the core investment thesis unchanged: Hoth remains a high-risk, binary-option play dependent on clinical data and non-dilutive financing.

Implication

The U.S. patent allowance for HT-KIT incrementally de-risks the platform and could improve partnering discussions, but it does not extend cash runway or generate revenue. Hoth's market cap of ~$11.8M trades just above its $8.1M net cash, reflecting low expectations for clinical success. The 2025 share count surge and ongoing cash burn of ~$3.3M per quarter imply further dilution is likely before any catalyst. Investors should monitor for HT-001 Phase 2 data and HT-KIT IND filing in the next 12-18 months as key value drivers. Until then, the risk/reward skews negative given the high probability of equity issuance; the attractive entry is closer to net cash levels.

Thesis delta

The U.S. patent allowance is a mild positive but does not shift the base-case scenario of wait-and-see. The investment thesis still hinges on HT-001 Phase 2 data and avoidance of severe dilution. No change to rating or conviction.